Literature DB >> 24854107

Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease.

Giulia Ambrosi1, Cristina Ghezzi2, Sara Sepe3, Chiara Milanese4, Cesar Payan-Gomez5, Cintia R Bombardieri3, Marie-Therese Armentero2, Roberta Zangaglia2, Claudio Pacchetti2, Pier Giorgio Mastroberardino6, Fabio Blandini7.   

Abstract

BACKGROUND: Parkinson's disease (PD) is a complex disease and the current interest and focus of scientific research is both investigating the variety of causes that underlie PD pathogenesis, and identifying reliable biomarkers to diagnose and monitor the progression of pathology. Investigation on pathogenic mechanisms in peripheral cells, such as fibroblasts derived from patients with sporadic PD and age/gender matched controls, might generate deeper understanding of the deficits affecting dopaminergic neurons and, possibly, new tools applicable to clinical practice.
METHODS: Primary fibroblast cultures were established from skin biopsies. Increased susceptibility to the PD-related toxin rotenone was determined with apoptosis- and necrosis-specific cell death assays. Protein quality control was evaluated assessing the efficiency of the Ubiquitin Proteasome System (UPS) and protein levels of autophagic markers. Changes in cellular bioenergetics were monitored by measuring oxygen consumption and glycolysis-dependent medium acidification. The oxido-reductive status was determined by detecting mitochondrial superoxide production and oxidation levels in proteins and lipids.
RESULTS: PD fibroblasts showed higher vulnerability to necrotic cell death induced by complex I inhibitor rotenone, reduced UPS function and decreased maximal and rotenone-sensitive mitochondrial respiration. No changes in autophagy and redox markers were detected.
CONCLUSIONS: Our study shows that increased susceptibility to rotenone and the presence of proteolytic and bioenergetic deficits that typically sustain the neurodegenerative process of PD can be detected in fibroblasts from idiopathic PD patients. Fibroblasts might therefore represent a powerful and minimally invasive tool to investigate PD pathogenic mechanisms, which might translate into considerable advances in clinical management of the disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extracellular Flux Analyzer; Fibroblasts; Parkinson's disease; Rotenone; Ubiquitin Proteasome System

Mesh:

Substances:

Year:  2014        PMID: 24854107     DOI: 10.1016/j.bbadis.2014.05.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  35 in total

1.  Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease.

Authors:  Chiara Milanese; Victor Tapias; Sylvia Gabriels; Silvia Cerri; Giovanna Levandis; Fabio Blandini; Maria Tresini; Sruti Shiva; John Timothy Greenamyre; Mark T Gladwin; Pier G Mastroberardino
Journal:  Antioxid Redox Signal       Date:  2017-09-21       Impact factor: 8.401

2.  Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.

Authors:  Giulia Ambrosi; Natasa Kustrimovic; Francesca Siani; Emanuela Rasini; Silvia Cerri; Cristina Ghezzi; Giuseppe Dicorato; Sofia Caputo; Franca Marino; Marco Cosentino; Fabio Blandini
Journal:  Neurotox Res       Date:  2017-03-11       Impact factor: 3.911

Review 3.  The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.

Authors:  Margrethe A Olesen; Francisca Villavicencio-Tejo; Rodrigo A Quintanilla
Journal:  Transl Neurodegener       Date:  2022-07-04       Impact factor: 9.883

4.  Rotenone-induced energy stress decompensated in ventral mesocerebrum is associated with Parkinsonism progression in rats.

Authors:  Qunhua Bai; Junlin He; Yong Tang; Shibo Wang; Jingfu Qiu; Yang Wang; Chao Yu
Journal:  Exp Ther Med       Date:  2016-05-18       Impact factor: 2.447

Review 5.  Noncoding RNAs in neurodegeneration.

Authors:  Evgenia Salta; Bart De Strooper
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

6.  Systems biology analysis of the proteomic alterations induced by MPP(+), a Parkinson's disease-related mitochondrial toxin.

Authors:  Chiara Monti; Heather Bondi; Andrea Urbani; Mauro Fasano; Tiziana Alberio
Journal:  Front Cell Neurosci       Date:  2015-02-02       Impact factor: 5.505

Review 7.  Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models.

Authors:  Rubén Fernández-Santiago; Mario Ezquerra
Journal:  Stem Cells Int       Date:  2015-11-30       Impact factor: 5.443

8.  A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patients.

Authors:  Cláudia M Deus; Susana P Pereira; Teresa Cunha-Oliveira; José Teixeira; Rui F Simões; Fernando Cagide; Sofia Benfeito; Fernanda Borges; Nuno Raimundo; Paulo J Oliveira
Journal:  Redox Biol       Date:  2021-06-08       Impact factor: 11.799

9.  Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson's Disease.

Authors:  M Murtaza; J Shan; N Matigian; M Todorovic; A L Cook; S Ravishankar; L F Dong; J Neuzil; P Silburn; A Mackay-Sim; G D Mellick; S A Wood
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

10.  Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease.

Authors:  Sara Sepe; Chiara Milanese; Sylvia Gabriels; Kasper W J Derks; Cesar Payan-Gomez; Wilfred F J van IJcken; Yvonne M A Rijksen; Alex L Nigg; Sandra Moreno; Silvia Cerri; Fabio Blandini; Jan H J Hoeijmakers; Pier G Mastroberardino
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.